NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Greystone Associates
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Syringe and Injector Device Innovation Lagging Drug Development in Some Key Areas Finds Greystone Research Associates - Greystone Research Associates examines the needs of injectable drug developers against the capabilities of evolving device designs - GreystoneAssociates.org
Syringe and Injector Device Innovation Lagging Drug Development in Some Key Areas Finds Greystone Research Associates

 

NewswireToday - /newswire/ - Amherst, NH, United States, 2013/12/17 - Greystone Research Associates examines the needs of injectable drug developers against the capabilities of evolving device designs - GreystoneAssociates.org.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Propelled by advances in materials science and design engineering software, progress in the healthcare sector is moving forward at an escalating rate. Drug delivery companies and their supply chain partners are being tested in this environment, as they strive to create devices and systems that can address the requirements of new drug therapies. The technology component of injection device design, development and fabrication has been arguably the most affected by this trend, and the strides that have been made in syringe and injector evolution have been impressive. But are injection devices at the forefront of this wave of innovation, or are they gating the launch of new injectables?

Not surprisingly, the answer is both. Advances in coatings and device designs have led to prefilled biologicals in patient-friendly drug-device combination products that were not possible just a few years ago. Prefilled drug cartridges have reduced the cost of injectable pens and autoinjectors, making them accessible to a larger segment of the chronically ill. Injectors with advanced features such as variable dosing, dose counters and audible cues are making self-administration safer for patients prescribed immune modulators with black box warnings. Similarly, dual chamber syringes and cartridges allow end-users to reconstitute injectable drugs without handling, measuring or manual dilution.

The other side of the title question is that, in spite of rapid progress in syringe and injector design and development, drug formulation is moving faster. Developers of advanced formulas that incorporate nanoparticles often have difficulty finding a device solution that keeps them on schedule. High-viscosity formulations that can be supplied and delivered in prefillable devices continue to challenge the industry. And certain protein and peptide drugs can create stability problems due to interaction with prefilled device materials, sometimes requiring long development delays or, if discovered post-launch, leading to product recalls and shortages.

To streamline the drug-device development process, drug developers are increasingly aligning themselves with device suppliers, increasing the level of concurrent engineering, identifying design challenges earlier and minimizing possible delays that could result. This trend represents risks for injectable drug firms competing for device solutions for their sophisticated formulations. It is also an opportunity for smaller device suppliers who are able to demonstrate the financial and technological resources to address the needs of injectable drug developers.

A new and comprehensive report on global injection device products and markets conducted by Greystone Research Associates is now available. The report Drug Injection Devices to 2018 provides analysis and assessments of drug injection devices across all major device categories syringes, pen injectors, autoinjectors, needle-free injectors and safety syringes and examines injectable drugs and combination products and their therapeutic markets, while also assessing market factors and market participants.

About Greystone Research Associates

Greystone Research Associates (greystoneassociates.org) is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Greystone Associates

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Syringe and Injector Device Innovation Lagging Drug Development in Some Key Areas Finds Greystone Research Associates

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Mark Smith - GreystoneAssociates.org 
603-595-4340 mksmith[.]greystoneassociates.org
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Greystone Associates securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Greystone Associates / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Bruker BioSpin Group Introduces New Online Platform to Connect NMR Scientists and Advance NMR Research in Europe
Health Canada Approves Ipsen’s Sohonos (Palovarotene Capsules) as the First Approved Treatment for Fibrodysplasia Ossificans Progressiva
LYSARC Partners with Veeva to Accelerate Innovation for Lymphoma Treatments
PharmaEssentia Selects Veeva Data Cloud to Support Launch of Novel Therapy for Rare, Chronic Blood Cancers
Transgene and NEC Announce Positive Preliminary Data from Phase I Studies of TG4050 - A Novel Individualized Neoantigen Cancer Vaccine
DSM Plans New Production Site for Bovaer® in Dalry, Scotland
Celltrion Pharm Selects TrackWise QMS for Scalability and Data Integrity
Ipsen Adds Another Program into its Pre-clinical R&D Oncology Pipeline through An Exclusive Worldwide Collaboration with Accent Therapeutics
Evaxion Biotech Lauded by Frost & Sullivan for Helping Develop Highly Targeted Therapies with its AI Immunology Platforms
Kyowa Hakko Acclaimed by Frost & Sullivan for its Non-GMO, Allergen-free, Immune Support Paraprobiotic Ingredient, IMMUSE™
DSM to Acquire First Choice Ingredients to Accelerate Growth in Food and Beverage
STEMCELL Technologies Launches Human Pluripotent Stem Cell Characterization and Banking Services in Partnership with WiCell
Biocon Selects TrackWise to Enable Enterprise Quality Management Across Global Biopharmaceutical Operations
STEMCELL Technologies and Hubrecht Organoid Technology to Partner on Non-Oncology Organoid Drug Screening Services
Ipsen and Exicure Enter into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  Limelon Advertising, Co.





 
  ©2022 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)